How we approach Philadelphia chromosome‐positive acute lymphoblastic leukemia in children and young adults
William B. Slayton, Kirk R. Schultz, Lewis B. Silverman, Stephen P. Hunger
Abstract
Treatment for children with Philadelphia chromosome-positive acute lymphoblastic leukemia has changed radically over the past 20 years. This type of leukemia used to have dismal prognosis, but today cure rates have improved with combination of cytotoxic chemotherapy and a tyrosine kinase inhibitor such as imatinib or dasatinib, with hematopoietic stem cell transplant reserved for patients who are at high risk based on slow response to therapy or who relapse. Treating these patients can be challenging particularly if they are not enrolled on a clinical trial. Here, we describe our approach to these patients.
Topics & Concepts
MedicineDasatinibImatinibLymphoblastic LeukemiaPhiladelphia chromosomeOncologyInternal medicineTyrosine-kinase inhibitorChemotherapyHematopoietic stem cell transplantationLeukemiaDiseaseChromosomal translocationCancerGeneGeneticsMyeloid leukemiaBiologyAcute Lymphoblastic Leukemia researchChronic Myeloid Leukemia TreatmentsChildhood Cancer Survivors' Quality of Life